Panel OKs 1st RSV Vaccine in Japan
15:43 JST, August 29, 2023
TOKYO (Jiji Press) — A health ministry panel Monday agreed to approve a vaccine developed by GSK PLC to protect people from the respiratory syncytial virus (RSV).
If the British pharmaceutical firm’s vaccine is formally approved, it will be the first for RSV available in Japan.
People eligible for the vaccination will be those aged 60 or older.
The main symptoms of RSV are fever and runny nose. RSV can cause pneumonia and bronchitis in infants and elderly people with underlying conditions.
The virus can be transmitted through contact or droplets, but there is no specific treatment for it.
The number of RSV infection cases in Japan grew briefly around May, when the country downgraded COVID-19 to a lower-risk category of infectious diseases. GSK said the vaccine was 82.6% effective in clinical trials with people aged 60 and older.
U.S. rival Pfizer Inc. has also filed for Japanese regulatory approval of an RSV vaccine.
"Society" POPULAR ARTICLE
-
Cherry tree falls on man on Sanneizaka steps leading to famous Kiyomizu Temple in Kyoto
-
Tokyo District Court Rules AI Cannot Be Issued Patents; Law Recognizes Only ‘Natural Persons’ as Inventors
-
Small Animal That Appears to be Mouse Found in Chojuku Bread Products; Some Brands on Same Production Line to be Recalled Voluntarily
-
Earthquake Hits Japan’s Ibaraki, Tochigi, Chiba Prefectures, No Risk of Tsunami
-
Man Repels Bear Attack in Hokkaido by Kicking its Face After Encountering 2 Bears While Sightseeing
JN ACCESS RANKING
- Weakening Yen Adds Complexity to BOJ’s Rate Hike Decisions; Rising Commodity Prices may Impact ‘Virtuous Cycle’ Efforts
- Japanese Seafood Exports to China Sink 57% in FY23; U.S. Becomes Largest Seafood Export Destination
- 70% of Japan Companies to Raise Pay Scales in FY 2024
- Minutes Show Policymaker Wants BOJ to Consider Further Rate Hikes Further
- 48.6% of Global Patent Applications Related to All-Solid-State Batteries Came from Japanese Firms; Panasonic Tops List